What We're Reading: Page 216
Industry reads hand-picked by our editors
Feb 14, 2020
-
Regulatory Focus
Internal FDA Emails Reveal How Price, Sanders's Pressure Played a Role in Competitor's Approval, Catalyst Claims
-
Endpoints News
Carl June on CRISPR, CAR–T and how the Vietnam War dropped him into medicine
-
Reuters
Gilead drug prevents type of coronavirus in monkeys; raises hope for China trials
Feb 13, 2020
-
The Wall Street Journal
Coronavirus-Drug Development Becomes a Top Focus at Gilead
-
New England Journal of Medicine
The Magic of Randomization versus the Myth of Real-World Evidence
-
Bloomberg
Elizabeth Holmes Gets Fraud Case Narrowed, Not Dismissed
Feb 12, 2020
-
MIT Technology Review
The coronavirus is the first true social-media "infodemic"
-
Bloomberg
Chinese Firm Makes Gilead Drug in Virus Fight, Raising IP Fears
-
The Philadelphia Inquirer
Merck to open outpost at Center City WeWork, as big companies see coworking as a passage into Philly
-
Healthcare Dive
CVS swings to $6.6B profit in 2019, buoyed by Aetna
Feb 11, 2020
-
Regulatory Focus
Interview With FDA's OND Director: Approval Standards, Transparency and More
-
STAT
Priscilla Chan's unglamorous quest to fight disease. (Mark is involved, too.)
-
The Economist
Run, don’t walk - The race to produce a vaccine for the latest coronavirus
-
Bloomberg
Trump Eyes Drug-Price Cuts After His Health-Care Record Assailed
Feb 10, 2020
-
The New York Times
China's Lavish Funds Lured U.S. Scientists. What Did It Get in Return?
-
Financial Times
The onetime Parisian street fighter who gave his company purpose
-
The Wall Street Journal
Pharma Megadeals Pass First Checkup
Feb 07, 2020
-
The Wall Street Journal
Where Are All the Women CEOs?
-
STAT
Lottery like no other offers a cutting-edge medicine — with lives on the line
-
The Washington Post
Doctor’s death from coronavirus sparks a digital uprising, rattling China’s leaders
-
Forbes
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Previous
